Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | MRGPRX1 | Q96LB2 | 4/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6360307 | 0.88 | MEN1 (0.41) | MEN1KMT2AEGFRMRGPRX1TRPA1 | |
| SCHEMBL30374325 | 0.86 | KMT2A (0.50) | MEN1KMT2AEGFRMRGPRX1TRPA1 | |
| SCHEMBL1456975 | 0.86 | KMT2A (0.50) | MEN1KMT2AEGFRMRGPRX1TRPA1 | |
| SCHEMBL3488162 | 0.84 | MRGPRX1 (0.44) | MEN1KMT2AEGFRMRGPRX1TRPA1 | |
| SCHEMBL30377367 | 0.78 | SCN9A (0.40) | MEN1KMT2AEGFRMRGPRX1TRPA1 | |
| SCHEMBL16378820 | 0.75 | KMT2A (0.56) | MEN1KMT2AEGFRMRGPRX1TRPA1 | |
| SCHEMBL24540615 | 0.74 | PIN1 (0.46) | EGFRMRGPRX1GPR119 | |
| SCHEMBL5196093 | 0.73 | KMT2A (0.50) | MEN1KMT2AEGFRMRGPRX1TRPA1 | |
| SCHEMBL14430205 | 0.73 | SCN9A (0.38) | MEN1KMT2AEGFRCYP1A2CYP2C19 | |
| SCHEMBL1456728 | 0.72 | TRPA1 (0.45) | MEN1KMT2AEGFRMRGPRX1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268446-B1 | METHOD FOR PRODUCING ASYMMETRICAL 4,6-BIS(ARYLOXY)PYRIMIDINE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-10-06 | — | — | EP | disclosed |
| EP-1268446-B1 | METHOD FOR PRODUCING ASYMMETRICAL 4,6-BIS(ARYLOXY)PYRIMIDINE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-10-06 | — | — | EP | disclosed |
| US-6734304-B2 | REACTING THE CORRESPONDING 4.6-DIHALOPYRIMIDINE COMPOUND WITH BASE; ONE POT PROCESS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-05-11 | — | — | US | disclosed |
| US-20030092723-A1 | Method for producing asymmetrical 4,6-bis(aryloxy)pyrimidine derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2003-05-15 | — | — | US | disclosed |
| EP-1268446-A1 | METHOD FOR PRODUCING ASYMMETRICAL 4,6-BIS(ARYLOXY)PYRIMIDINE DERIVATIVES | Bayer CropScience AG (DE) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001072719-A1 | METHOD FOR PRODUCING ASYMMETRICAL 4,6-BIS(ARYLOXY)PYRIMIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092723-A1 | Method for producing asymmetrical 4,6-bis(aryloxy)pyrimidine derivatives | DPYD, TYMS, TYMP | MEN1 4310/4885KMT2A 2163/4885EGFR 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.